PCRX Deadline: PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Pacira BioSciences, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Pacira securities is from August 2, 2023, to August 8, 2024, and the lead plaintiff deadline is March 14, 2025 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [3]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [3]. - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Allegations - The lawsuit alleges that statements made by Pacira during the Class Period were misleading, particularly regarding the patent protections on Exparel, which were critical for the company's growth [4]. - It is claimed that Pacira misrepresented the strength of its patent protections, knowing that the '495 patent was not as robust as publicly stated [4]. - The lawsuit asserts that when the true nature of the patent protections became known, investors suffered damages [4].